Chargement en cours...
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors
Inhibition of PARP is a promising therapeutic strategy for homologous recombination–deficient tumors, such as BRCA1-associated cancers. We previously reported that BRCA1-deficient mouse mammary tumors may acquire resistance to the clinical PARP inhibitor (PARPi) olaparib through activation of the P-...
Enregistré dans:
| Publié dans: | Cancer Discov |
|---|---|
| Auteurs principaux: | , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2012
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7518105/ https://ncbi.nlm.nih.gov/pubmed/23103855 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0049 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|